CSA Announces Partnership With NTP Radioisotopes

CSA Announces Partnership With NTP Radioisotopes

Tuesday, 28 March 2023

JOHANNESBURG: Cricket South Africa (CSA) is today pleased to announce a partnership with NTP Radioisotopes for the Betway Pink Day that will be held at the Wanderers Stadium on Sunday, 2 April 2022.

NTP Radioisotopes, a subsidiary of the South African Nuclear Energy Corporation (Necsa), is a leading global producer and supplier of nuclear medicine and radiation-based products and services.

Originally conceived in the early 1970s to supply the local South African market with commercial radiopharmaceuticals, this state-owned public company is now among the world’s top producers and distributors of key medical radioisotopes such as molybdenum-99 (Mo-99), a radioisotope-based diagnostic imaging agent used for the early detection of, amongst other, cardiovascular, neurological and neuroendocrine diseases. For targeted therapy products, NTP produces iodine-131 and lutetium-177, which is used for the treatment of various cancers such as prostate, neuroendocrine and breast.

The Basics of Targeted Therapy in Cancer care is to “Treat what you see”. Each patient’s cancer journey is unique, and therefore it is critical to match the right therapy with the right patient at the right time. NTP are developing more of these delivery drugs to target other high prevalence cancers, such a breast cancer and skin cancer.

NTP Radioisotopes, which supplies nearly a third of the world’s Mo-99, and exports radiation products to over 50 countries, will have an activation at the Betway Pink Day event to create awareness on nuclear medicine. This will give fans the opportunity to learn more about NTP Radioisotopes’ work in this specialised field.

Commenting on the partnership, CSA Chief Executive Officer, Pholetsi Moseki said;

“CSA is keen to partner with entities that have the pedigree and knowledge systems which could be beneficial to our fans.This is part of our concerted efforts to avail information in the comfort of stadium experience, that could enrich theiroutlook.

“We are excited to partner with NTP Radioisotopes to bring nuclear medicine education to the throng of cricket fans that are expected to attend the Betway Pink Day ODI match. We also thank them for their contribution, which will add value to the prestige and success of this calendar charity event.”

Thabo Tselane, Group Managing Director of NTP Radioisotopes SOC, said;

“NTP Radioisotopes is excited to join hands with the CSA on initiatives such as the Betway Pink ODI, aimed at raising awareness and contributing to the development of treatment solutions for breast cancer. We are committed to ensuring that our patients have access to innovative solutions within the nuclear medicine sector, through investments in our manufacturing facilities and research & development initiatives. We are confident that this partnership will assist in creating awareness around nuclear medicine diagnosis and treatment options for cancer, and their superior benefits, to the medical fraternity and the public at large.

“NTP will continue to be a leading manufacturer and global supplier of diagnostics and therapeutics products likeMolybdenum-99, Lutetium-177 and Iodine-131, so that together we can increase accessibility of Nuclear medicine for life saving therapies across Africa.”


Issued by: Cricket South Africa – Corporate Communications


Cricket South Africa (CSA), an affiliate of the South African Sports Confederation and Olympic Committee (SASCOC) and a full member of the International Cricket Council (ICC), is the national governing body for the sport of cricket in South Africa and administers all aspects of South African cricket, men, and women, both in the professional and amateur sphere.


NTP Radioisotopes SOC Ltd is a fully owned subsidiary company of NECSA.  Established on 1 October 2003 with a specific mandate of producing and marketing radioisotopes and radiation products and services and sell them to the global market. NTP Radioisotopes SOC Ltd is an integrated manufacturer and global  supplier of radiochemical, radiopharmaceutical, and irradiation products & services, with a footprint in over 50 countries worldwide. One of the top global leaders in the production of (API) nuclear medicine.